Becton, Dickinson and Company BDX

NYSE · Healthcare · Medical - Instruments & Supplies

$212.78

Close on Fri, 20 Nov 2026 · market value $58B

What the price is betting on

Below its record

At $213, the price assumes revenue shrinks about 0.3% a year for five years, from $19.5B to about $19.1B by FY2031. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes−0.3%
Analysts, next two years2.8%
Last 3 years0.1%

Revenue growth a year. The price figure comes from a reverse DCF at a 6.6% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than BDX? Check up to 5 of your stocks at once, free, no account.

0$10B$20B$30B$19.5B'23'24'25'26'27'28'29'30'31What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$233

Base

$263

Bull

$296

Today $213

  • Bear $233. Cash flow grows 1% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $263. Cash flow grows 3% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $296. Cash flow grows 5% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2027$19.4B$19.7B, on the path
  3. FY2028$19.3B$20.6B, on the path
  4. FY2029$19.3B$21.4B, on the path
  5. FY2030$19.2B$22B, on the path
  6. FY2031$19.1B$22.9B, on the path

Each year's revenue at −0.3% growth from $19.5B in FY2026.

At a glance

Healthcare · Medical - Instruments & Supplies · listed on NYSE

Revenue, FY2026
$19.5B
Growth, 3 years a year
0.1%
Cash margin
14%
Net debt
$15.6B
Shares, 3-year change
−2.9%
Dividend yield
2%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.